Diabetes disease progression in Goto-Kakizaki rats: Effects of salsalate treatment

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 381-389

  Wang, Xi ^a   Dubois, Debra C ^a   Cao, Yanguang ^a   Jusko, William J ^a   Almon, Richard R ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adiponectin; Inflammation; Salicylates; Type 2 diabetes

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; INSULIN; MESSENGER RNA; SALSALATE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FOOD INTAKE; GENE; GENE EXPRESSION; GENE LOCATION; GLUCOSE BLOOD LEVEL; GOTO KAKIZAKI RAT; HYPERGLYCEMIA; IFIT1 GENE; IIGP1 GENE; INFLAMMATION; INSULIN BLOOD LEVEL; LIPOLYSIS; LIVER; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; RAT MODEL; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84905440276     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S65818     Document Type: Article

References (34)

1. Maruthur NM. The growing prevalence of type 2 diabetes: increased incidence or improved survival? Curr Diab Rep. 2013;13(6): 786-794.
2. World Health Organization. Geneva: Global status report on noncommunicable diseases 2010. Available from:http://www.who.int/nmh/publications/ncd_report_full_en.pdf. Accessed July 24, 2014.
3. Nowlin SY, Hammer MJ, D'Eramo Melkus G. Diet, inflammation, and glycemic control in type 2 diabetes: an integrative review of the literature. J Nutr Metab. 2012;2012:542698.
4. Kempf K, Rose B, Herder C, Kleophas U, Martin S, Kolb H. Inflammation in metabolic syndrome and type 2 diabetes: impact of dietary glucose. Ann N Y Acad Sci. 2006;1084:30-48.
5. Navarro-Gonzalez J, Mora-Fernandez C, Gomez-Chinchon M, Muros M, Herrera H, Garcia J. Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. Int J Immunopathol Pharmacol. 2010;23(1):51-59.
6. Mann S, Beedie C, Balducci S, et al. Changes in insulin sensitivity in response to different modalities of exercise: a review of the evidence. Diabetes Metab Res Rev. 2014;30(4):257-268.
7. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia. 2005;48(6):1038-1050.
8. Pietraszek A, Gregersen S, Hermansen K. Acute effects of dietary fat on inflammatory markers and gene expression in first-degree relatives of type 2 diabetes patients. Rev Diabet Stud. 2011;8(4):477-489.
9. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2): 191-198.
10. Reymond P, Farmer EE. Jasmonate and salicylate as global signals for defense gene expression. Curr Opin Plant Biol. 1998;1(5):404-411.
11. Ebstein W. Zur therapie des Diabetes mellitus, insbesondere über die Anwendung des salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift. 1876;13:4. German.
12. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108(3):437-446.
13. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289-294.
14. Goldfine AB, Conlin PR, Halperin F, et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013;56(4):714-723.
15. Goldfine AB, Fonseca V, Jablonski KA, et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346-357.
16. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265(5174):956-959.
17. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109(10):1321-1326.
18. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013;50(4):537-543.
19. Goto Y, Suzuki K, Ono T, Sasaki M, Toyota T. Development of diabetes in the non-obese NIDDM rat (GK rat). Adv Exp Med Biol. 1988;246:29-31.
20. Portha B, Giroix MH, Tourrel-Cuzin C, Le-Stunff H, Movassat J. The GK rat: a prototype for the study of non-overweight type 2 diabetes. Methods Mol Biol. 2012;933:125-159.
21. Nie J, Xue B, Sukumaran S, Jusko WJ, DuBois DC, Almon RR. Differential muscle gene expression as a function of disease progression in Goto-Kakizaki diabetic rats. Mol Cell Endocrinol. 2011;338(1-2):10-17.
22. Almon RR, DuBois DC, Lai W, Xue B, Nie J, Jusko WJ. Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats. J Endocrinol. 2009;200(3):331-346.
23. Xue B, Sukumaran S, Nie J, Jusko WJ, DuBois DC, Almon RR. Adipose tissue deficiency and chronic inflammation in diabetic Goto-Kakizaki rats. PLoS One. 2011;6(2):e17386.
24. Cao Y, DuBois DC, Sun H, Almon RR, Jusko WJ. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats. J Pharmacol Exp Ther. 2011;339(3):896-904.
25. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990): 457-463.
26. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009;58(12):2718-2725.
27. Mofredj A, Howaizi M, Grasset D, et al. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47(7): 1649-1654.
28. Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology. 2005;42(4):880-885.
29. Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52(3):385-393.
30. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285(3):E527-E533.
31. Oana F, Takeda H, Hayakawa K, et al. Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectin. Metabolism. 2005;54(8):995-1001.
32. Kadowaki T, Yamauchi T. Adiponectin receptor signaling: a new layer to the current model. Cell Metab. 2011;13(2):123-124.
33. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295.
34. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25.